Literature DB >> 10693158

Assessing the efficacy of treatments for the deficit syndrome of schizophrenia.

B Kirkpatrick1, A Kopelowicz, R W Buchanan, W T Carpenter.   

Abstract

The primary, enduring negative symptoms found in some patients with schizophrenia have become the focus of clinical treatment trials, but there has been no consensus on the best methods for approaching this area. In future trials, a number of issues need to be considered, including analytic strategies, the limitations in instruments used to measure negative symptoms, and study design. An appropriate design for establishing the efficacy of treatments for the deficit syndrome is proposed.

Entities:  

Mesh:

Year:  2000        PMID: 10693158     DOI: 10.1016/S0893-133X(99)00122-0

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  19 in total

1.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

Review 2.  Methodological issues in current antipsychotic drug trials.

Authors:  Stefan Leucht; Stephan Heres; Johannes Hamann; John M Kane
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

3.  A few methodologic issues of note.

Authors:  William T Carpenter
Journal:  Schizophr Bull       Date:  2008-09-11       Impact factor: 9.306

4.  Fifty Years: Do Over or Move Forward.

Authors:  William T Carpenter
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

Review 5.  Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.

Authors:  Ellen R Bradley; Joshua D Woolley
Journal:  Neurosci Biobehav Rev       Date:  2017-05-12       Impact factor: 8.989

6.  Progress in the study of negative symptoms.

Authors:  Brian Kirkpatrick
Journal:  Schizophr Bull       Date:  2014-03       Impact factor: 9.306

7.  Clinically Meaningful Gaps Between Clinical Trials and Patient Treatment.

Authors:  Robert W Buchanan; William T Carpenter
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

Review 8.  Amisulpride: a review of its use in the management of schizophrenia.

Authors:  M P Curran; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

9.  5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice.

Authors:  Vladimir M Pogorelov; Ramona M Rodriguiz; Jianjun Cheng; Mei Huang; Claire M Schmerberg; Herbert Y Meltzer; Bryan L Roth; Alan P Kozikowski; William C Wetsel
Journal:  Neuropsychopharmacology       Date:  2017-03-15       Impact factor: 7.853

10.  Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task.

Authors:  Daniel Scott; Jane R Taylor
Journal:  Behav Brain Res       Date:  2013-11-14       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.